Ixabepilone in Treating Young Patients With Refractory Solid Tumors

Trial ID or NCT#

NCT00331643

Status

not recruiting iconNOT RECRUITING

Purpose

This phase II trial is studying how well ixabepilone works in treating young patients with refractory solid tumors. Drugs used in chemotherapy, such as ixabepilone, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.

Official Title

Phase II Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Children and Young Adults With Refractory Solid Tumors

Eligibility Criteria

Ages Eligible for Study: 1 Year to 35 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Show Less

Investigator(s)

Neyssa Marina

Contact us to find out if this trial is right for you.

Contact

Norman Lacayo
6507235535

View on ClinicalTrials.gov